B
Bull
Bull · 25%AZTR
$0.27
Scenario price
$0.177
-0.008 (-4.79%)At close
Loading chart…
- High
- 0.189
- Open
- 0.182
- VWAP
- 0.18
- Vol
- 1.03M
- Mkt Cap
- 3.80M
- Low
- 0.171
- Amount
- 184.51K
- EV/EBITDA, TTM
- 0.00
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live bio therapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, chronic, xerotic (abnormally dry), and scaly skin disease.
AI analysis of Azitra Inc (AZTR)
holdAzitra Inc. (AZTR) is currently not a strong buy due to its high RSI of 74.12, indicating it may be overbought, and a significant year-to-date change of -36.53%, suggesting ongoing struggles despite recent gains.
Valuation Metrics
The current forward P/E ratio for Azitra Inc (AZTR) is 0.00, compared to its 5-year average forward P/E of -2.66.
Alphio AI Price Scenarios for AZTR
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
7.008-21PRnewswireAzitra Regains Compliance with NYSE American Listing Standards
7.008-21NewsfilterAzitra Regains Compliance with NYSE American Listing Standards
- 5.007-15Newsfilter
Azitra Reports Promising Anti-Wrinkle Results from Skin Studies
8.506-23NASDAQ.COMTenon Files S-1, Stock Surges 77.57%
- 8.506-16Newsfilter
Azitra to Showcase Pipeline Progress at BIO International Convention
AZTR FAQ — answered by Alphio AI
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live bio therapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, chronic, xerotic (abnormally dry), and scaly skin disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Azitra Inc. (AZTR) is currently not a strong buy due to its high RSI of 74.12, indicating it may be overbought, and a significant year-to-date change of -36.53%, suggesting ongoing struggles despite recent gains.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.